Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 9, Issue 2, 2007, Pages 175-185

  Rosenstock, J ^a   Baron, M A ^b   Camisasca, R P ^b   Cressier, F ^b   Couturier, A ^b   Dejager, Sylvie ^b  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dipeptidyl peptidase 4; Incretin hormones; Pioglitazone

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INCRETIN; PIOGLITAZONE; VILDAGLIPTIN;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 33846827085     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00698.x     Document Type: Article

References (28)

1. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Riddle MC, Rosenstock J. Oral monotherapy and combination therapy. In: Cefalu WT, Gerich JE, LeRoith D eds. The CADRE Handbook of Diabetes Management. New York: Medical Information Press, 2004; 127-144.
3. American Diabetes Association. American Diabetes Association (ADA) guidelines: Clinical practice recommendations. Diabetes Care 2006; 29 (Suppl. 1): S1-S85.
4. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
5. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
6. Shah BR, Hux JE, Laupacis A, Zinman B, van WC. Clinical inertia in response to inadequate glycemic control: Do specialists differ from primary care physicians? Diabetes Care 2005; 28: 600-606.
7. Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
8. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
9. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-698.
10. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423-428.
11. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
12. van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
13. Roden M, Laakso M, Johns D et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med 2005; 22: 1101-1106.
14. Burkey BF, Li X, Bolognese L et al. Combination treatment of a DPP-IV inhibitor NVP-LA237 with pioglitazone completely normalized glucose tolerance in adult obese zucker rats. Diabetes 2002; 51 (Suppl. 2): A338-A339.
15. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
16. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
17. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-1547.
18. Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 1529-1533.
19. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Foley JE. LAF237 is a DPP-4 inhibitor that improves model-assessed β-cell function in drug-naive patients with type 2 diabetes. Diabetologia 2004; 47 (Suppl. 1): A284-A285.
20. D'Alessio DA, Watson CE, He YL et al. Restoration of an acute insulin response to glucose (AIRg) in drug-naïve patients with type diabetes (T2DM) by 3-month treatment with vildagliptin. Diabetes 2006; 55 (Suppl. 1): A108.
21. Radikova Z, Azuma K, Thomas E et al. Metabolic effects of incretin hormones I. Diabetologia 2006; 49: 401.
22. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1year. Diabetes Care 2005; 28: 1936-1940.
23. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
24. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004; 28: 783-789.
25. Matsui J, Terauchi Y, Kubota N et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 2004; 53: 2844-2854.
26. Del Prato S, Marchetti P. Targeting insulin resistance and beta-cell dysfunction: The role of thiazolidinediones. Diabetes Technol Ther 2004; 6: 719-731.
27. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
28. Writing Team for the Diabetes Control Trial. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.